Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 15/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336517 | 0.83 | MAP3K12 (0.42) | MAPTALDH1A1MAP3K12LMNAGFER | |
| SCHEMBL3413852 | 0.76 | MAP3K12 (0.47) | MAP3K12 | |
| SCHEMBL2577774 | 0.76 | MAP3K12 (0.49) | MAP3K12MTORPIK3CA | |
| SCHEMBL15399356 | 0.75 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAMAP3K13 | |
| SCHEMBL15399039 | 0.75 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAMAP3K13 | |
| SCHEMBL19221771 | 0.75 | MAP3K12 (0.44) | MAP3K12MTORPIK3CAMAP3K13 | |
| SCHEMBL30912434 | 0.75 | MAPT (0.45) | MAPTMEN1ALDH1A1THRBKMT2A | |
| SCHEMBL30912529 | 0.75 | MAPT (0.45) | MAPTMEN1ALDH1A1THRBKMT2A | |
| SCHEMBL13657915 | 0.75 | MAPT (0.45) | MAPTMEN1ALDH1A1THRBKMT2A | |
| SCHEMBL3413859 | 0.75 | MAPT (0.45) | MAPTMEN1ALDH1A1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885MEN1 544/4885ALDH1A1 4333/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 501/4885MEN1 1218/4885ALDH1A1 3674/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAPT 470/4885MEN1 544/4885ALDH1A1 4333/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885MEN1 636/4885ALDH1A1 4184/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885MEN1 636/4885ALDH1A1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.